Chugai Seiyaku Kabushiki Kaisha

Yoshikazu Nishimura

Masahiro Nishimoto

Yoshiyuki Furuta

Satoshi Tsuchiya

Atsushi Matsuo

Hirotaka Kashiwagi

Masahide Aoki

Satoshi Tanida

Nobuyuki Hori

Kyoko Oguri

Takahiro Kawai

Shoshin Yoshida

Takuma Kamon

Hiroko Ogawa

Tsutomu Sato

Hitoshi Yoshino

Takuya Shiraishi

Toru Esaki

Naoki Okamoto

Jaeyoung Choi

Kazumi Morikawa

Yoshitake Kanbe

Yoshiaki Isshiki

Masateru Ohta

MyungHwa Kim

JaeChon Jo

Akemi Mizutani

HeeAn Kwon

Tomoya Kotake

HyunSuk Lim

Wayne Wen Lai

Tatsuya Tamura

Toshihiko Makino

Toshiaki Nagafuji

The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.

Pyrazolopyridine derivative having GLP-1 receptor agonist effect

The present invention provides the compound, 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound.

The present invention relates to a compound represented by the following formula (1): wherein W, X, Y, R, R, R, R, m and n are as defined in the claims, or a pharmacologically acceptable salt thereof.

Spiroimidazolone derivative

The present invention provides compounds represented by formula (1) below and pharmacologically acceptable salts thereof: wherein R, R, R, and Rare as defined in the claims.

Hydantoin derivative

The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): in which

Compounds with hydroxycarbonyl-halogenoalkyl side chains

Compounds with hydroxycarbonyl-halogenoalkyl side chain

Compounds represented by the general formula (1):

Aromatic amine derivatives having NOS inhibiting action

Growing community of inventors

Shizuoka, Japan

Yoshikazu Nishimura